Document is current
Any future updates will be listed below
-
Authors
Zürcher, Nicole R.
Walsh, Erin C. https://orcid.org/0000-0002-9573-7165
Phillips, Rachel D.
Cernasov, Paul M. https://orcid.org/0000-0001-7183-393X
Tseng, Chieh-En J. https://orcid.org/0000-0003-0592-335X
Dharanikota, Ayarah
Smith, Eric https://orcid.org/0000-0003-0785-8192
Li, Zibo
Kinard, Jessica L. https://orcid.org/0000-0002-4286-5454
Bizzell, Joshua C.
Greene, Rachel K.
Dillon, Daniel https://orcid.org/0000-0002-1977-700X
Pizzagalli, Diego A. https://orcid.org/0000-0002-7772-1143
Izquierdo-Garcia, David
Truong, Kinh
Lalush, David
Hooker, Jacob M.
Dichter, Gabriel S. https://orcid.org/0000-0003-3407-5417
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R21MH110933, K23MH113733, R21MH110933)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 14 November 2020
Revised: 30 November 2020
Accepted: 7 December 2020
First Online: 11 January 2021
Conflict of interest
: Over the past three years, D.A.P. has received funding from NIMH, Brain and Behavior Research Foundation, the Dana Foundation, and Millennium Pharmaceuticals; consulting fees from, BlackThorn Therapeutics, Boehreinger Ingelheim, Compass Pathway, Engrail Therapeutics, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; one honorarium from Alkermes; stock options from BlackThorn Therapeutics. All other authors report no biomedical financial interests or potential conflicts of interest.
